ICLN vs XBI
iShares Global Clean Energy ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.38% for ICLN.
- • ICLN pays a higher dividend yield (1.20%).
Side-by-side metrics
| Metric | ICLN | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.38% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.20% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $1.94B | $10.92B |
YTD return | 1.37% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.38 | 1.01 |
P/E ratio | 20.54 | — |
Last price | $16.35 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
ICLN top holdings
| FSLR | First Solar Inc | 8.60% |
| NXT | Nextpower Inc | 8.04% |
| IBE.MC | Iberdrola SA | 7.04% |
| BE | Bloom Energy Corp Class A | 6.20% |
| 600900.SS | China Yangtze Power Co Ltd Class A | 5.84% |
| AXIA3.SA | Axia Energia | 4.17% |
| VWS.CO | Vestas Wind Systems AS | 3.32% |
| ORA | Ormat Technologies Inc | 3.07% |
| 9502.T | Chubu Electric Power Co Inc | 2.86% |
| ENPH | Enphase Energy Inc | 2.52% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About ICLN
ICLN (iShares Global Clean Energy ETF) is Global clean energy and renewable power companies. Managed by iShares, the fund carries $1.9B in assets under management, an expense ratio of 0.38%, a dividend yield of 1.20%. Its largest holding is First Solar Inc (FSLR), which represents 8.6% of the portfolio. Basic Materials is the fund's largest sector exposure at 1.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.